Humacyte announces Phase 3 trial results for tissue engineered vessel in female dialysis patients

Filed June 10, 2026 · Period ending June 10, 2026 · ~1 min read

Key Changes

• high

  Company disclosed results from Phase 3 clinical trial (V012) testing its acellular tissue engineered vessel (ATEV) for arteriovenous access in female end-stage renal disease patients requiring hemodialysis—a key regulatory milestone for its lead product.

  Item 7.01 view on EDGAR →
• medium

  Released new investor presentation to accompany the clinical data announcement, which will be used in upcoming investor calls and conferences to provide additional context on the trial results.

  Item 7.01 view on EDGAR →